Skip to main content
. Author manuscript; available in PMC: 2021 Jul 30.
Published in final edited form as: Mol Pharm. 2019 Dec 27;17(2):392–403. doi: 10.1021/acs.molpharmaceut.9b00589

Figure 2.

Figure 2.

Modeling of azide anchoring to tumor ECM with intratumoral fluid flow. (A) Schematic diagram of NHS-ester injection, aminolysis, and hydrolysis as well as COMSOL Multiphysics model parameters. (B) 0D model estimating the change in the concentration of the injected azide-sNHS ester, hydrolyzed species, and ECM-anchored azides over time. The expected reaction kinetics is further layered on a three-dimensional (3D) space-dependent model that leads to the results in (C). (C) Number of anchored azides available to bind to systemic DBCO molecules over mm from the center of the infusion needle in the tumor.